TriSalus Life Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(unaudited, in thousands except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $7,349 | $5,193 | $21,170 | $12,790 |
| Cost of goods sold | 1,004 | 589 | 2,887 | 2,023 |
| Gross profit | 6,345 | 4,604 | 18,283 | 10,767 |
| Operating expenses: | ||||
| Research and development | 4,219 | 9,506 | 14,729 | 22,066 |
| Sales and marketing | 6,138 | 4,689 | 18,829 | 11,430 |
| General and administrative | 4,727 | 9,025 | 13,310 | 17,498 |
| Loss from operations | (8,739) | (18,616) | (28,585) | (40,227) |
| Other income (expense): | ||||
| Interest income | 158 | 116 | 347 | 187 |
| Interest expense | (1,142) | (4) | (2,022) | (13) |
| Loss on equity issuance | — | — | — | (5,691) |
| Extinguishment of tranche liability | — | 19 | — | 1,520 |
| Change in fair value of SEPA, warrant, and revenue base redemption liabilities | 4,974 | (2,831) | (1,521) | 660 |
| Change in fair value of contingent earnout liability | 2,360 | 19,904 | 12,061 | 19,904 |
| Other expense, net | (13) | (13) | (210) | (56) |
| Loss before income taxes | (2,402) | (1,425) | (19,930) | (23,716) |
| Income tax benefit (expense) | 3 | — | (7) | (8) |
| Net loss available to common stockholders | $(2,399) | $(1,425) | $(19,937) | $(23,724) |
| Deemed dividend related to Series B-2 preferred stock down round provision | $— | $— | $— | $(2,981) |
| Undeclared dividends on Series A preferred stock | $(803) | $(458) | $(2,405) | $(458) |
| Net loss attributable to common stockholders | $(3,202) | $(1,883) | $(22,342) | $(27,163) |
| Net loss per common share, basic and diluted | $(0.12) | $(0.14) | $(0.91) | $(5.72) |
| Weighted average common shares outstanding, basic and diluted | 26,501,597 | 13,173,422 | 24,588,500 | 4,749,849 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.